Migami has acquired the worldwide rights to cosmeceutical applications and the Asia / Middle East rights to the therapeutic applications of the proprietary peptide portfolio. These novel peptide molecules offer broad-based anti-infective and anti-inflammatory solutions for multiple diseases and disorders, ranging from yeast infection to organ-transplant rejection, and have the potential to alter the way many clinical problems are treated. These technologies are based on an extensive background of over 30 years of academic research on peptide molecules derived from -Melanocyte Stimulating Hormone ("MSH"), an endogenous molecule that modulates inflammatory and immune responses. The combination of both anti-infective and anti-inflammatory properties suggests that these peptides may be a more complete therapeutic option than steroids, which reduce inflammation but increase the risk of infection, or antibiotics, which are not effective in inhibiting inflammation. In addition, topical cosmeceutical applications offer an attractive, near-term opportunity in the high-growth, anti-aging markets.